Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 2, 2007, Pages 907-915

  Barnett, Joshua M ^a   McCollum, Gary W ^a   Fowler, Jessica A ^a   Duan, James J W ^b   Kay, Jesse D ^a   Liu, Rui Qin ^b   Bingaman, David P ^c   Penn, John S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DPC A27668; DPC A37668; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; OXYGEN; PRINOMASTAT; RO 319790; UNCLASSIFIED DRUG; APYRASE; DPC-A37668; ENZYME INHIBITOR; HYDROXAMIC ACID; N1 [2,2 DIMETHYL 1 [(METHYLAMINO)CARBONYL]PROPYL] N4 HYDROXY 2 (2 METHYLPROPYL)BUTANEDIAMIDE; ORGANIC COMPOUND; PYRIDINE DERIVATIVE; RO 31-9790;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; GENETIC MANIPULATION; IMAGING SYSTEM; NEWBORN; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; RAT; RETINA; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; THERAPY EFFECT; TISSUE FIXATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WILD TYPE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; GENE SILENCING; HUMAN; INJECTION; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VITREOUS BODY;

ANIMALS; ANIMALS, NEWBORN; APYRASE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GENE SILENCING; HUMANS; HYDROXAMIC ACIDS; INFANT, NEWBORN; INJECTIONS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; ORGANIC CHEMICALS; OXYGEN; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RETINA; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; VITREOUS BODY;

EID: 33847694887     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0082     Document Type: Article

References (42)

1. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications (review). Biochem Pharmacol. 2001;61:253-270.
2. Berglin L, Sarman S, van der Ploeg I, et al. Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice. Invest Ophthalmol Vis Sci. 2003;4403-4408.
3. Migatti P, Rifkin DB. Plasminogen activations and matrix metalloproteinase in angiogenesis. Enzyme Protein. 1996;49:117-137.
4. Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natn Acad Sci. 1983;80:2956-2960.
5. Blasi F, Vassalli JD, Dano K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors (review). J Cell Biol. 1987; 104:801-804.
6. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS. Skriver L. Plasminogen activators, tissue degradation, and cancer (review). Adv Cancer Res. 1985;44:139-266.
7. Kristensen P, Larsson LI, Nielsen LS, Grondahl-Hansen J, Andreasen PA, Dano K. Human endothelial cells contain one type of plasminogen activator. FEBS Lett. 1984;168:33-37.
8. Saksela O. Plasminogen activation and regulation of pericellular proteolysis (review). Biochimica et Biophysica Acta. 1985;823: 35-65.
9. Soini Y, Hurskainen T, Hoyhtya M. Oikarinen A, Autio-Harmainen H. 72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer; a study by in situ hybridization. J Histochem Cytochem. 1994;42:945-951.
10. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998;58:1048-1051.
11. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737-744.
12. York JR, Landers S, Kirby RS, Arbogast PG, Penn JS. Arterial oxygen fluctuation and retinopathy of prematurity in very-low-birthweight infants. J Perinatol. 2004;24:82-87.
13. Flynn JT, O'Grady GE, Herrera J, Kushner BJ, Cantolino S, Milam W. Retrolental fibroplasia: I. Clinical observations. Arch Ophthalmol. 1977;95:217-223.
14. Nelson I. Disorders of the Eye. London: WB Saunders; 1996;15: 1790.
15. Nelson Textbook of Pediatrics, vol 15.
16. Foos RY, Chronic retinopathy of prematurity. Ophthalmology. 1985;92:563-574.
17. Anonymous. Multicenter trial of cryotherapy for retinopathy of prematurity: 3 1/2-year outcome: structure and function. Arch Ophthalmol. 1993;111:339-344.
18. Phelps DL. Retinopathy of prematurity (review). Pediatr Rev. 1995;16:50-56.
19. Penn JS, Rajaratnam VS, Collier RJ, Clark AF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2001;42:283-290.
20. Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res. 1994;36:724-731.
21. Penn JS, Rajaratnam VS. Inhibition of retinal neovascularization by intravitreal injection of human rPAI-1 in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2003;44:5423-5429.
22. Smith LEH, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35: 101-111.
23. Lutty GA, McLeod DS. A new technique for visualization of the human retinal vasculature. Arch Ophthalmol. 1992;110:267-276.
24. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci. 1993;34:576-585.
25. 2 variation determines the severity of oxygen-induced retinopathy in newborn rats. Invest Ophthalmol Vis Sci. 1995;36:2063-2070.
26. Penn JS, McCollum GW, Barnett JM, Werdich XQ, Keopke KA, Rajaratnam VA. Angiostatic effect of penetrating ocular injury: role of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2006;47:405-414.
27. Puyraimond A, Weitzman JB, Babiole E, Menashi S. Examining the relationship between the gelatinolytic balance and the invasive capacity of endothelial cells. J Cell Sci. 1999;112:1283-1290.
28. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064-3073.
29. Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res. 2000;70:419-428.
30. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science. 2000;289:1202-1206.
31. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA. 1996;93: 7069-7074.
32. Ohno-Matsui K, Uetama T, Yoshida T, et al. Reduced retinal angiogenesis in MMP-2-deficient mice. Invest Ophthalmol Vis Sci. 2003; 44:5370-5375.
33. Sarman S, van der Ploeg I, Seregard S. Retinal vascular development and pathologic retinal angiogenesis are not impaired in matrix metalloproteinase-2 deficient mice. Curr Eye Res. 2005;30: 259-267.
34. Rohan RM, Fernandez A, Udagawa T, Yuan J, D'Amato RJ. Genetic heterogeneity of angiogenesis in mice. FASEB J. 2000;14:871-876.
35. Penn JS, Henry MM. Assessing retinal neovascularization in an animal model of proliferative retinopathy. Microvasc Res. 1996; 51:126-130.
36. Fayer JL, Zannikos PN, Stevens JC, Luo Y, Sidhu R, Kirkesseli S. Lack of correlation between in vitro inhibition of CYB3A-mediated metabolism by a PPAR-gamma agonist and its effect on he clinical pharmacokinetics of midazolam, and in vivo probe of CYP3A activity. J Clin Pharm. 2001;41:305-316.
37. Maurer T, Fung HL. Comparison of methods for analyzing kinetic data from mechanism-based enzyme inactivation: application to nitric oxide synthase (abstract). AAPS Pharmsci. 2000;2:E8.
38. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457-10461.
39. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA. 1996;93:4851-4856.
40. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch of Ophthalmol. 1996;114:66-71.
41. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC beta inhibition with LY333531. Invest Ophthalmol Vis Sci. 1998; 39:171-179.
42. Bullard LE, Qi X, Penn JS. Role for extracellular signal-responsive kinase-1 and -2 in retinal angiogenesis. Invest Ophthalmol Vis Sci. 2003;44:1722-1731.